Abstract
The fourth most frequent cancer in the world is Gastric cancer and also the second leading cause of cancer-related fatalities. Despite substantial research into new diagnostic and therapeutic agents, patients with advanced stomach cancer have a low quality of life and a dismal prognosis, and treatment is mostly cytotoxic chemotherapy. A deeper knowledge of the underlying molecular pathologies, as well as their application toward the development of innovative therapeutic strategies, is essential for improving the quality of life and survival of gastric cancer patients. Chemokines are a family of tiny proteins linked to cytoskeletal rearrangements, directed several cell movements throughout development and physiology, and the host immunological responses by interrelation with G-protein coupled receptors. Presently there is growing proof that chemokines are involved in the development and progression of malignancies, in addition to their involvement in the immune system. Cell transfer in and out of the tumor microenvironment in gastric cancer is regulated by CXC chemokines and chemokine receptors. CXC chemokines and their receptors can affect carcinogenesis directly by regulating tumor transformation, survival, growth, metastasis, and invasion and also by indirectly controlling angiogenesis and tumor-leukocyte interactions. The significance of CXC chemokines and their receptors in the formation, progression, and metastasis of gastric cancers will be discussed in this review, as well as their therapeutic potential for gastric cancer.
Keywords
Chemokine; Chemokine receptor; Gastric neoplasm; Therapeutic target